NCT06833268View on ClinicalTrials.gov

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

CompletedOBSERVATIONAL
Enrollment

228

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
HER2-positive Breast Cancer
Interventions
OTHER

No drug

This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol.

Trial Locations (1)

10013

Flatiron Health, Inc, New York

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY